Newsroom

The Ivy Brain Tumor Center has announced the launch of a new Spanish-language website, recognizing the importance of providing clinical trial information in multiple languages to patients and caregivers in the U.S. and around the world. 

Dr. Joe Tedesco is taking the country by storm as he sets out to ride his bike from coast to coast in honor of brain tumor survivor Nate Tomlin. Covered by 12 News, Dr. Tedesco's fundraiser is gaining traction and he has increased his goal to $20,000! Check out the full story!

InBusiness Phoenix Magazine's latest cover story they detail the Ivy Brain Tumor Center as one of the "top-ranked healthcare organizations that provide top-notch care, are innovative and known for research excellence.”

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, will evaluate evaluate AZD1390 in a Phase 0/1b clinical trial with patients diagnosed with recurrent grade IV gliomas.

The Ivy Brain Tumor Center announced the opening of a new Phase 0/1b clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant (ATM) kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas.

The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).

The Hazen's presented a $1.5 million check to doctors, physicians and researchers at the Ivy Brain Tumor Center at the Barrow Neurological Institute. Nicole is receiving treatment and care at the Ivy Center after she was diagnosed in July 2020 with glioblastoma, a rare form of brain cancer.

StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, announced they raised $340,000 for the Ivy Brain Tumor Center at Barrow Neurological Institute.

GlaxoSmithKline Plc is partnering with the Ivy Brain Tumor Center to test one of its key oncology medicines against brain cancer as the British pharmaceutical giant looks to expand the drug’s use.

The Ivy Center in collaboration with UCSF Department of Neurological Surgery is pleased to announce a new clinical trial of GSK’s niraparib (ZEJULA) – an FDA-approved drug to treat ovarian cancer – for patients with newly diagnosed glioblastoma and recurrent high-grade gliomas.